Brief: Oncolytics Biotech Completes Initial Safety Phase Enrollment For Goblet Trial's New Pancreatic Cancer Cohort
03/12/2024 12:06
Dec 3 (Reuters) - Oncolytics Biotech ONC.TO :
* ONCOLYTICS BIOTECH® REPORTS COMPLETION OF INITIAL SAFETY
PHASE
ENROLLMENT FOR GOBLET TRIAL'S NEW PANCREATIC CANCER COHORT
* ONCOLYTICS BIOTECH INC - DSMB RECOMMENDS CONTINUED
ENROLLMENT IN
GOBLET STUDY COHORT 5
* ONCOLYTICS BIOTECH INC - ENROLLMENT TO RESUME PENDING
APPROVAL
FROM PAUL EHRLICH INSTITUTE
* ONCOLYTICS BIOTECH INC - ADDITIONAL UPDATES EXPECTED IN
2025
Source text: ID:nCNW2XKp7a
Further company coverage: ONC.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer